Is Palm Oil Bad for You? Against Liquid Oils It Raised LDL About 9 mg/dL in 26 Trials. The Cancer Worry Rests on Animal Studies.

“Palm oil is not an outright poison.” That is how Google’s AI answer opens when you ask whether palm oil is bad for you, and among the pages it cites are a palm-oil company’s blog, a chocolate maker that sells palm-oil-free chocolate and a cardiac centre’s video [1]. Plenty of people ask: “is palm oil bad for you” is searched about 22,200 times a month in the United States (from a paid keyword database, pulled 20 October 2026) [1].

For your cholesterol, it depends on what the palm oil replaces. In place of liquid vegetable oils, it raised LDL by about 9 mg/dL in a pooling of 26 trials; in place of butter, it comes out ahead in a network of trials, though the two trials in the 2015 pooling that set it directly against butter or lard found LDL about the same, and a third, against lard, found it lower on palm oil. [2] [3] [4] We found no randomised trial that gave people palm oil, or took it away, and counted heart attacks, strokes or deaths, and the cancer worry rests on animal studies of a contaminant that refining puts into the oil [5].

Two terms first. LDL is the cholesterol that guidelines and cholesterol drugs mainly target, the kind people call bad; HDL is the kind usually called good. Both are reported in mg/dL, milligrams per decilitre, the unit on an American lab report. The trials report millimoles per litre, and we give their figures in brackets.

Does palm oil increase cholesterol?

Against the oils it usually replaces, yes. The clearest pooling is a 2015 meta-analysis, a study that combines trials to get one estimate, from the National University of Singapore [2]. It gathered 27 trials, published from 1985 to 2011, that fed people palm oil or palm olein, its liquid part, for two to sixteen weeks against an oil low in saturated fat: sunflower, safflower, canola, olive, soybean, peanut and others. 807 people started them, and in 20 of the trials the researchers supplied every meal [2].

In the 26 that measured it, LDL ended about 9 mg/dL higher on palm oil (0.24 mmol/L) [2]. The confidence interval, the range the true average probably sits in, ran from about 5 to 13.5 mg/dL, by our conversion: a range for an average across trials, not a forecast for any one person [2]. HDL was a little higher on palm oil too, by about 0.8 mg/dL (0.02 mmol/L), and triglycerides, the other blood fat on the test, could not be told apart [2].

Who ran the trial, and how, mattered. In the 19 randomised trials, where chance decided who got which oil, or in which order, LDL was about 12 mg/dL higher on palm oil (0.31 mmol/L); in the 7 that were not randomised it was about 1 mg/dL, with a range that included no difference (0.03) [2]. The amount mattered too: about 24 mg/dL higher (0.63) in the five trials where palm oil supplied 30% or more of the day’s calories, about 9 (0.24) where it supplied 20% to under 30%, and about 2 (0.06), with a range that included no difference, below 20% [2]. Thirty percent of a 2,000-calorie day is about 67 grams of oil, a little under 5 tablespoons, by our arithmetic.

Before printing a pooled figure we look for the biggest study inside it. Here it is a Malaysian trial of 110 boys aged 16 and 17, not randomised, about one in seven of the people who started, by our arithmetic; it sits among the non-randomised trials, whose pooled result was close to zero, so it is not what produces the 9 mg/dL [2].

Three cautions, all from the paper itself. The trials varied a great deal: I-squared, the share of the spread between the trials’ results that is more than chance would produce, was 83%, and fell to 27.5% among the randomised trials once the amount of oil and the comparison oil were allowed for [2]. Small trials reporting bigger rises hinted that some less striking trials may never have been published, which the authors call possible publication bias, though they note the small trials also fed more oil and were more often randomised [2]. And in the randomised trials, palm oil raised LDL about 38% less than a standard formula based on its fatty acids predicts [2].

Most of these trials, 15 of the 27, were paid for partly or wholly by industry, and they found smaller rises than the government-funded ones: about 4.6 mg/dL against 21.7 (0.12 and 0.56 mmol/L) [2]. But they had also fed less palm oil, and once the amount was allowed for, the funding gap was no longer clear [2].

LDL on palm oil, set against each oil: the 2015 pooling’s subgroups
Palm oil compared withTrialsLDL on palm oil (mg/dL)
Safflower oil high in oleic acid [2]2About 22 higher (0.57 mmol/L)
Sunflower oil high in oleic acid6About 21 higher (0.54)
Sunflower oil high in linoleic acid2About 13 higher (0.33); range includes no difference
Soybean oil3About 13 higher (0.33); range includes no difference
Canola oil4About 8 higher (0.20)
Rice bran, corn, safflower and mixtures5About 8 higher (0.21); range includes no difference
Olive oil4About 4 higher (0.11); range includes no difference
Peanut (groundnut) oil3About 6 lower (−0.15); range includes no difference
Butter or lard2About the same (−0.01); range includes no difference
Each row pools whole trials, a handful at a time, and the rows are separate answers, not slices of one result. The mg/dL figures are our conversion of the paper’s mmol/L figures, which are in brackets. “Range includes no difference” means the confidence interval crossed zero. The trials fed different amounts of oil, and the amount moved the result as much as the oil did.

A second team, drawing largely on the same trials with some newer ones, found the same direction. A 2020 review from the University of Malaya found LDL about 9 mg/dL higher on palm oil than on oils rich in monounsaturated fat (0.24 mmol/L) in 16 crossover studies of 365 people, where each person ate both diets in turn, and graded that evidence low; against oils rich in polyunsaturated fat, about 10 mg/dL higher (0.26) in five crossover studies of 114 people, graded moderate [6]. One study of 60 people that ran the two groups side by side found the reverse, LDL about 11 mg/dL lower on palm oil (−0.28 mmol/L) [6]. Counting that study, the review’s overall figure against monounsaturated oils was about 8 mg/dL (0.20 mmol/L) [6]. Against polyunsaturated oils, three side-by-side studies of 152 people varied widely, and counting them the overall figure was about 17 mg/dL (0.44 mmol/L), with a range from almost nothing to about 34 higher [6]. About half that review’s trials, it notes, were paid for by a palm-oil organisation or by a company supplying the comparison oil [6]. A 2021 umbrella review, a review of the reviews that drew on the earlier poolings, put the gaps at about 9.2 mg/dL against monounsaturated oils and 3.4 against polyunsaturated ones [7].

The largest pooling by count, 51 studies in 2014, found total cholesterol, LDL and HDL significantly higher on palm oil than on diets rich in stearic acid or in monounsaturated or polyunsaturated fat, and most of the same markers lower than on diets rich in two other saturated fats, lauric and myristic acids; the rise against the unsaturated fats was not significant in young people or in diets lower in fat [8]. We read it in full, in an archived copy of the journal’s page. It was paid for by a Milan university and an Italian chocolate and confectionery company, which the paper says has “a financial interest in products containing” palm oil; that company funded one author for this work and two others in the previous three years, and a fourth author had been funded by an Italian confectionery and pasta industry association that, the paper says, “might have an interest in the outcome of the study”. The paper says the funders had no role in the analysis [8].

Two poolings found no clear difference. What they are made of matters. One, in 2019, was paid for by Malaysia’s palm oil board, and three of its seven authors give the board’s nutrition unit as their affiliation [9]. It set palm olein against a mix of oils that included coconut oil and lard: LDL about 2 mg/dL lower on palm olein overall, with a range from about 11 lower to 6 higher (−0.06 mmol/L) [9]. That overall figure mixes two kinds of comparison. Against coconut oil and lard, in five comparisons, LDL was about 19 mg/dL lower on palm olein (−0.50 mmol/L). Against the liquid oils, the comparison this page rates, it came out higher, by ranges that included no difference: about 7 mg/dL higher than on oils rich in monounsaturated fat, in nine comparisons, from about 4 lower to 17 higher (0.17 mmol/L), and about 2 mg/dL higher than on soybean oil, in two (0.04 mmol/L) [9].

The other, also 2019, pooled 11 trials, and its own table lists the same board as the funder of 10 of them; LDL about 2 mg/dL lower, with a range reaching about 0.4 higher (−0.05 mmol/L) [10]. Its rule was to include only randomised trials, yet 42.6% of the weight behind that figure, by its own chart, is one study its own table calls a before-after study: the Malaysian study of 110 boys that is also the biggest in the 2015 pooling, where it sits among the non-randomised trials [10] [2]. The section below on why reviews disagree comes back to both.

Two appraisals have been published since. In February 2024 the WHO published a rapid overview of the systematic reviews comparing palm oil with other vegetable oils, prepared for it by an evidence centre at Stellenbosch University in South Africa, with searches to January 2022 [11]. It left the 2014 pooling and the 2019 palm-olein pooling out of its analysis, citing their funding, and used the other five reviews [11]. Judged on AMSTAR 2, a standard checklist of how well a review was done, the 2015 pooling, the other 2019 pooling and a 2018 review of heart outcomes came out “critically low quality”, meaning more than one critical flaw, and the 2020 review “low quality”; one flaw it named in the 2015 and 2019 poolings was mixing randomised and non-randomised trials [11]. It judged the network analysis’s credibility “sufficient”, on a separate checklist for network analyses, while noting that it had not accounted for things that could change the effect or explored why its trials differed [11]. Its conclusion on LDL: the average rise reported by the largest review in each comparison, against vegetable oils in general and against monounsaturated and polyunsaturated oils separately, was above 0.13 mmol/L, about 5 mg/dL by our conversion, the line it drew, for want of an agreed one, for a change that could matter to heart risk [11]. Its own sections are less sure. It called the effect on LDL in the polyunsaturated-oil crossover trials possibly “trivial”, read the 2019 pooling whose trials the palm oil board mostly funded as showing a “trivial” effect on LDL too, called the network’s comparisons of palm oil with each of nine liquid oils “mostly indicative of trivial increases”, and summed up the reviews’ LDL results as “variable” [11].

A 2024 umbrella review, searched to July 2023, graded the evidence that palm oil raises total and LDL cholesterol “low to very low certainty”, the bottom two of the four grades the standard scale uses, and said palm olein has “minimal impact on lipid parameters” against liquid oils [12]. Three of its eight authors give the palm oil board’s nutrition unit as their affiliation, it reports no funding and no conflicts, and its palm olein conclusion rests on one review: the board-funded 2019 pooling above [12].

Which oils are not healthy?

On LDL, the fats that came out worst in the largest comparison were not oils: butter and lard. A network meta-analysis, which ranks many options at once by linking up trials that each compared two of them, put 54 trials and 2,065 people together across 13 oils and fats [3]. For each 10% of calories swapped, about 200 calories on a 2,000-calorie day, palm oil left LDL about 9 mg/dL lower than butter (0.24 mmol/L), as did every other oil in it except hempseed oil [3]. Against lard, beef fat and coconut oil, palm oil could not be told apart [3].

Against the liquid oils, the network could separate only one: sunflower oil left LDL about 4 mg/dL lower than palm oil (0.10 mmol/L) [3]. Soybean, canola, corn, olive and safflower oil came out lower than palm oil or level with it, by ranges that included no difference, by our reading of its table [3]. The authors say the network’s estimates more often came from comparisons pieced together through other oils than from trials that set two fats side by side [3]. Our vegetable oil verdict reads the same table for soybean oil, and our canola verdict for canola.

The direct evidence on butter is thin. The one trial in the 2015 pooling that set palm oil against butter, 29 men, not randomised, and the one against lard, together found LDL about the same on palm oil (−0.01 mmol/L) [2]. A third direct trial, whose lard arm is not in that pooling, points the other way for lard: in China, 120 young men with normal cholesterol were randomly assigned to palm oil, soybean oil, peanut oil or lard for six weeks, and LDL ended significantly lower on palm oil than on lard, having fallen about 13% from the start on palm oil and risen about 31% on lard [4]. A Malaysian palm oil research institute paid for it [4]. One randomised trial set butter against palm stearin, the hard part of palm oil left when the liquid is drawn off: 24 adults with normal cholesterol ate each fat for three weeks under controlled feeding, and LDL ended 11% to 13% higher on butter, in both its low-carbohydrate and high-carbohydrate groups. Malaysia’s palm oil board paid for it [13]. So “better than butter” rests mostly on the network’s indirect comparisons and one small trial of palm oil’s hard fraction.

Which is healthier, groundnut oil or palm oil?

For LDL, the trials could not separate them. Groundnut oil is peanut oil, and in the 2015 pooling’s three peanut-oil trials LDL was about 6 mg/dL lower on palm oil, with a range from about 15 lower to 3 higher (−0.15 mmol/L) [2]. Olive oil was close too: about 4 mg/dL higher on palm oil in four trials, with a range from about 1 lower to 10 higher [2]. The clear gaps were against sunflower, safflower and canola oils, as the table above shows. Peanut oil is not one of the network’s 13 fats [3]. Olive oil has its own verdict.

Is palm oil bad for your heart?

That is a different question from cholesterol. We found no randomised trial that gave people palm oil, or took it away, and counted heart attacks, strokes or deaths [5].

A 2018 systematic review from Malaysia’s Institute for Medical Research looked for any study of palm oil and heart disease or stroke, trial or observational, up to mid-2017 [14]. It found three reports from one Costa Rican study and one study of whole countries, which it counted for both heart deaths and stroke deaths, graded all of it very low, and said it “could not establish strong evidence for or against” [14].

The Costa Rican study is the closest thing to a test in people. It compared 2,111 adults who had survived a first heart attack with 2,111 people from the same areas, matched by age and sex [15]. People who cooked with palm oil had 1.33 times the odds of a heart attack of people who cooked with soybean oil low in trans fat, with a range from 1.08 to 1.63, after allowing for smoking, alcohol, diabetes, blood pressure, waist, activity, income, calories and fibre; 1.00 would mean no difference [15]. Against other oils, mostly sunflower, the figure was 1.23, with a range from 0.99 to 1.52, so no difference was still possible; against soybean oil high in trans fat, 1.14, from 0.84 to 1.56 [15]. Palm-oil users were poorer and more often smokers, 29% against 14% of people using other oils, and a study that compares people after the fact can adjust for such things but cannot rule them out [15].

A second, smaller case-control study, published in 2021 after that review’s search, comes from three hospitals in southern Ethiopia. It compared 140 patients with ischaemic heart disease, the kind caused by narrowed heart arteries, with 417 patients at the same hospitals who had minor complaints unrelated to the heart, recruited from whoever was available rather than chosen at random [16]. Of the heart patients, 79.3% cooked with palm oil, against 56.1% of the others; after allowing for education, high blood pressure, exercise, fruit and vegetables and obesity, palm oil users had 2.12 times the odds of heart disease of people who cooked with sunflower oil, with a range from 1.23 to 3.63 [16]. Its authors note that a study like this cannot show which came first, and that people’s recall of their own habits may be biased [16].

The study of whole countries is looser still. Across 23 countries from 1980 to 1997, each extra kilogram of palm oil eaten per person per year went with 68 more heart deaths per 100,000 people aged 50 and over in ten developing countries, with a range from 21 to 115, and 17 more in thirteen high-income ones [17]. Studies like this follow countries, not people, and cannot tell who ate the oil. Our vegetable oil verdict sets the same study beside other country comparisons.

What has been tested in trials is cutting saturated fat in general, the fat that makes up about half of palm oil; our saturated fat verdict rates that Supported, for modestly fewer cardiovascular events, which is not the same as testing palm oil. The 2015 pooling’s authors estimate, from trials of cholesterol-lowering, that the 9 mg/dL rise might mean about 6% more coronary deaths and events; that is their extrapolation, not something a palm oil trial measured [2].

Is palm oil cancerous?

We found no study in people that measured palm oil eaten against cancer [5]. The worry comes from two kinds of animal study, and the first is about refining, not the oil.

When vegetable oils are refined, a step heats them above 200°C (392°F), and in it contaminants called glycidyl esters form; in the gut they are thought to release almost all their glycidol [18]. Europe’s food safety authority, EFSA, found the highest levels in palm oil: in samples from 2012 to 2015, an average of about 4,000 micrograms of glycidol per kilogram of palm oil (3,955 µg/kg), against 166 to 650 in rapeseed, soybean, sunflower, coconut and maize oils, and 421 in palm kernel oil [18]. A microgram is a millionth of a gram. Glycidol caused tumours in several organs of rats and mice given it for two years, probably by damaging DNA, and the WHO’s cancer agency classes it as probably carcinogenic to humans [18].

EFSA judges a contaminant like that by its margin of exposure, how far people’s intake sits below the dose that caused tumours in animals, and counts a margin of 25,000 or more as low concern [18]. For teenagers and adults, older people included, the margin ran from 102,000 at average intake down to 9,300 for the highest eaters; for babies, toddlers and older children, from 34,000 down to 4,900; for infants fed only formula it was about 5,500 on average and 2,100 at the high end; and EFSA concluded that margins below 25,000 “indicate a health concern” [18]. A second contaminant from the same step, 3-MCPD, damaged the kidneys of rats; EFSA’s 2018 update found adults’ intake under its safe daily limit and young children’s slightly over it at the high end [19].

Europe acted on the oil: EU law now caps glycidyl esters at 1,000 micrograms per kilogram in oils sold to shoppers or used in food, about a quarter of palm oil’s 2012 to 2015 average by our arithmetic, and at 50 in powdered infant formula [20]. In the United States, scientists at the Food and Drug Administration testing infant formulas bought from late 2017 to early 2019 found the levels had fallen since 2016 at three of four makers, and say two of them appear to use palm oil refined to cut these contaminants [21]. We read that paper as its abstract.

What those opinions settle is that refined palm oil carried more of these contaminants than other oils, and that at some intakes, young children’s and infants’ above all, the margin is too thin for EFSA’s comfort. What they do not settle is whether anyone has got cancer from palm oil: the tumour evidence is from animals, and EFSA’s measurements predate the EU caps [18] [20].

The second is a 2021 study in mice. Once oral tumours had appeared, mice were fed a diet rich in palm oil, rich in olive oil, or a standard one for ten days; tumour cells from the palm-oil mice spread more when they were transplanted into new mice [22]. It is about the spread of an existing cancer, in mice, not about whether the oil starts one.

One cancer-related hazard in palm oil really has been found on American shelves, and it is not the oil. In a survey published in 2016, FDA scientists tested red palm oils bought in Washington, DC-area shops selling African foods, and online; four of the 20 brands contained Sudan IV, a red dye banned from food in the US and the EU, while the red palm oil supplements they tested had none above the detection limit [23]. The paper calls the Sudan dyes toxic and carcinogenic, and also notes that the WHO’s cancer agency places them in its group 3, which that agency defines as “not classifiable as to its carcinogenicity to humans” [23].

Is refined palm oil good for health?

Not better than the liquid oils, on the trials: refined palm oil is the kind that raised LDL against them, and the kind that carried the most refining contaminants in EFSA’s data [2] [18]. Refined palm oil, red palm oil and palm kernel oil are three different products, and the evidence does not transfer between them. The trials in the 2015 pooling used the most typical palm oil or palm olein; the pooling left out red palm oil, palm kernel oil and palm stearin, the hard fraction [2].

Red palm oil is refined differently, to keep the carotenoids that colour it and that the body turns into vitamin A [24]. A 2017 pooling of nine randomised trials, mostly in children and pregnant or breastfeeding women in India and Africa, found it cut the share of people short of vitamin A by about 45% in three trials (a risk ratio of 0.55, with a range from 0.37 to 0.82) and raised blood vitamin A in seven trials of 1,127 people [24]. The review was part-funded by Malaysia’s palm oil board [24]. That is a finding for people short of vitamin A, not a reason for anyone else to eat it.

Which plant-based oils are high in saturated fat?

Coconut oil and palm kernel oil, at about four fifths saturated: USDA’s food data put them at 82.5 and 81.5 grams of saturated fat per 100 grams [25]. Palm oil is about half: the Costa Rican study’s analysis of the palm oil sold there found 49.7% saturated, 39.0% monounsaturated and 9.6% polyunsaturated fat, and the 2015 pooling gives 40% to 50% [15] [2]. For comparison, butter’s fat is about 63% saturated, by our arithmetic from USDA’s figures, and lard’s about 39% [25]. The liquid oils are far lower, and our canola and olive oil verdicts give their figures.

How is palm kernel oil different from palm oil?

It comes from the seed, not the fruit, and it is a different fat. Palm oil’s saturated fat is mostly palmitic acid; palm kernel oil’s is mostly lauric acid, 47.0 grams per 100, like coconut oil’s [2] [25]. How lauric acid behaves in feeding trials, and why its effect on heart disease is uncertain, is on our saturated fat verdict. Palm kernel oil was not among the 13 fats in the network analysis [3], and we rate nothing about it on this page.

Is palm oil a seed oil?

No. Palm oil is pressed from the flesh of the oil palm’s fruit; palm kernel oil comes from the seed inside it [2] [1]. The seed oils people argue about, soybean, canola, sunflower and the rest, have their own verdict, which also sets out two overfeeding trials that compared palm oil with sunflower oil for liver fat.

Who these trials were done on

The 2015 pooling’s trials were in adults and older teenagers, with normal or raised cholesterol, in the United States, Australia, Europe and Asia, with a few elsewhere; ages ran from teenagers to people in their sixties, and the trials lasted two to sixteen weeks [2]. The network’s trials ran three to 27 weeks in 2,065 people whose average ages ranged from 22 to 84 [3]. The heart studies were Costa Rican adults under 75 [15] and adult patients at three hospitals in southern Ethiopia [16]. The vitamin A trials were mostly in children and pregnant or breastfeeding women where deficiency is common [24].

So read yourself against them. The trials fed palm oil as 12% to 43% of the day’s calories [2]. A medical school’s consumer health letter notes that in the United States palm oil “accounts for a very small percentage of overall fat consumption” [1]. If yours comes in the odd cookie, you are far below the amounts the trials fed. If you cook with it daily, as in the soups and stews where red palm oil can be eaten “in large amounts (several cups) daily”, in the FDA scientists’ words, you may be in the range the trials tested [23]. If your LDL is high, what to eat is a question for a clinician or dietitian who knows your numbers; the foods that lower cholesterol have their own verdict.

If palm oil raises LDL, why do some reviews say it doesn’t?

This section is the desk’s own reasoning, and it is labelled as such. Several poolings looked at palm oil and blood fats, and two of them found no clear rise at all. Here are three ways to fit that together, each rated.

Answer one: it depends what the palm oil is set against. Within the 2015 pooling, the rise was clear against oleic sunflower and safflower oils and canola, and not clear against olive or peanut oil [2]. A pooling whose trials leaned on the second kind of comparison would find less, and one that mixed in solid fats would find less still. That is what happened inside the 2019 palm-olein pooling: its overall null splits into LDL about 19 mg/dL lower on palm olein than on coconut oil and lard, and about 7 mg/dL higher, by a range that included no difference, than on the monounsaturated oils [9]. That the rise depends on the comparison oil is measured, in the 2015 pooling and inside that one; that it explains the other 2019 pooling’s null is a surmise, and its trials used a mix of comparison oils [10].

Answer two: the dose. The rise was clear when palm oil supplied a fifth or more of the day’s calories and not below that [2], and the 2014 pooling found the rise not significant in diets lower in fat [8]. But this explains less of the disagreement than it seems: the 2019 pooling that found no clear rise drew on trials feeding palm oil at 17.5% to 24% of calories, where its table says, most of them at or above the fifth at which the 2015 pooling did find one [10]. Both tables are measured; the comparison is ours, and it cuts against this answer.

Answer three: who ran and paid for the trials. Non-randomised trials found close to no rise, and industry-funded trials found less than government-funded ones, though mostly because they fed less oil [2]. The 2014 pooling saw the same pattern: the rise was less evident in trials the palm oil board funded than in those others paid for, and its authors note that most Asian trials were board-funded, in young people with normal cholesterol, on lower-fat diets, so those things travel together [8]. The design point reaches one null pooling directly: 42.6% of its weight is the non-randomised Malaysian study of 110 boys [10]. That much is measured, in the reviews’ own tables and chart. One null pooling was written partly by the palm oil board’s staff, and the other’s trials were mostly paid for by the same board [9] [10]; WHO’s 2024 overview left the first of them, and the 2014 pooling, out of its analysis, citing their funding, and the newest review of reviews, written partly by the same board’s staff, rests its view of palm olein on that same pooling [11] [12]. That is an observation about who ran the research, not a measurement of bias, and we mark it as one.

Put the three together and here is what we think is true, stated plainly so you can disagree with it: palm oil behaves like the saturated fat it half is: the more of it that replaces a liquid oil, the higher LDL goes, and a little of it in place of olive or peanut oil barely registers.

What we could not find, and would like to: a trial that gave people palm oil or a liquid oil for years and counted heart attacks. We found no randomised trial that did [5]. Until one reports, the case against palm oil’s effect on the heart runs through LDL, the two case-control studies we found, in Costa Rica and Ethiopia, and a study of 23 countries. If you know of such a trial, the corrections line on this site is open.

Where “palm oil raises your cholesterol” came from

The research is old, and it did not set out to judge palm oil. In 1985 a US trial fed 20 patients liquid diets with 40% of their calories from fat, as palm oil, high-oleic safflower oil or high-linoleic safflower oil; in the 12 with normal triglycerides, both safflower oils lowered LDL, equally, compared with the palm oil diet [26]. Palm oil was simply the saturated fat. We read that trial as its abstract.

The framing came from the top. In 2003 a WHO and FAO expert report called the evidence “convincing” that myristic and palmitic acids raise the risk of cardiovascular disease, while noting that coconut and palm oil “may be an important source of energy for the poor” [27]. Palmitic acid is palm oil’s main saturated fat [2]. A palm oil promotion council questioned the report’s palm-oil concerns while it was being drafted, a 2019 paper in the WHO’s own journal reports [28]. Two decades on, WHO’s page for an expert group on tropical oils, which first met in May 2024, says WHO “is planning to develop” a guideline on them, and lists none among its publications [29]; its 2024 overview of the reviews is, its publication page says, evidence for interim policy talks while countries wait [11].

Then it spread in both directions. Google’s AI answer today says palm oil is high in saturated fat and that liquid oils are better for long-term heart health, and the related searches ask whether palm oil is bad for your heart, whether it raises cholesterol and whether it is cancerous [1]. A cardiac centre’s video in the same answer is titled “Could the Palm Oil You Use Every Day Be Harming Your Heart?” [1]. On the other side, a health publisher’s page ranking for the same search says palm oil “generally appears to have beneficial effects” on heart risk factors and quotes the 51-study pooling only for its comparisons with trans fats and with lauric and myristic acids, not for the one in which palm oil came out worse [1] [8].

And it sells, both ways. A chocolate maker’s page cited in the AI answer warns that palm oil’s saturated fat can lead to “increased levels of cholesterol and an increased risk of heart disease”, beside a link to its palm-oil-free chocolates [1]. A palm-oil company’s blog in the same answer lists “palm oil is bad for the heart” as a misconception and says there is no cholesterol in palm oil; a plantation company’s page says the same, and both quote a 2015 review’s line that palm oil “does not have incremental risk for cardiovascular disease” [1] [30]. That review is a narrative review, not a pooling of trials [30]. The same paragraph of the blog concedes that some studies found palm oil produced LDL “in slightly higher amounts than other vegetable oil” [1], and that is the finding that matters: the cholesterol line is true and beside the point, because what raises LDL in the blood is saturated fat, and the same blog puts palm oil at roughly half saturated fat [27] [1].

None of this is aimed at anyone who eats palm oil. By one count it is in around half of everyday packaged products [28], and nobody chose it fat by fat. It is the sellers on both sides, the ones warning you off it to sell you the alternative and the ones telling you it is cholesterol-free, who are selling a simpler answer than the trials gave.

What this is rated, and what the rating covers

Supported — for the claim that palm oil, eaten in place of liquid vegetable oils, raises LDL cholesterol.

It is rated Supported because the 2015 and 2020 poolings, drawing largely on overlapping trials, found the same rise, as did the 2014 pooling and a 2021 review of reviews; because the rise is larger in the randomised trials and at higher doses; because it is what palm oil’s fatty acids predict [2] [6] [8] [7]; and because WHO’s 2024 overview, which set aside the two poolings with funding conflicts, concluded that the largest remaining review in each comparison reported a rise above its line for one that could matter [11]. It is not Established because the trials were short, small and varied, and the poolings re-use many of the same ones, with signs that some went unpublished; because the network analysis could separate palm oil only from sunflower oil; because the rise was not clear against olive or peanut oil; because WHO’s appraisers rated the methods of the 2015 pooling critically low and the 2020 review low, and a 2024 review of reviews graded the evidence low to very low certainty; and because two poolings found no clear difference overall, though against the liquid oils alone one of them leaned toward higher LDL on palm olein, and the other rests 42.6% on one non-randomised study [2] [3] [11] [12] [9] [10].

Each part, rated alone, in words. That palm oil is better than butter for your LDL: Preliminary. The network analysis puts it ahead, mostly through indirect comparisons. Of the three direct trials of palm oil against animal fats we read, the two in the 2015 pooling, one against butter and one against lard, found LDL about the same, and a Chinese trial found it lower on palm oil than on lard; the one direct trial of palm oil itself against butter we read is small and was not randomised, and a randomised trial of palm stearin, palm oil’s hard fraction, found LDL 11% to 13% higher on butter, paid for by the palm oil board [3] [2] [4] [13].

That palm oil causes heart attacks: Preliminary. The evidence in its favour is the LDL rise, a case-control study in Costa Rica, a smaller hospital-based one in Ethiopia and a study of 23 countries; we found no randomised trial that counted heart attacks [15] [16] [17] [14] [5].

That palm oil causes cancer: Preliminary. The evidence in its favour is from animals: a contaminant that refining forms, most of all in palm oil, caused tumours in rats and mice, and a palm-oil diet made existing tumours spread in mice. We found no study in people that measured palm oil eaten against cancer [18] [22] [5].

That red palm oil raises vitamin A in people short of it: Supported, in nine small trials pooled by a review the palm oil board part-funded [24].

What is not rated here: palm oil’s effect on forests and wildlife, a real question and a different one; palm kernel oil on its own; palm vitamin E supplements; and the frame above, which is this desk’s reasoning from the evidence rather than a result the evidence delivered. It is marked as ours so that you can weigh it as ours.

This is journalism, not medical advice. If you are managing high cholesterol, what you eat, and whether you need a drug, belongs with a clinician or dietitian who knows your numbers. How we read a study, and what each tier means, is set out here.

Sources
[1] Search data from a paid keyword database: the monthly US search volume for “is palm oil bad for you”, and Google’s results, People Also Ask questions, related searches and AI answer for the same phrase, all pulled 20 October 2026. Pages the answer cites or ranks, read by us on 20 October 2026: a palm-oil company’s blog post (4 July 2023, updated August 2025); a plantation company’s FAQ (November 2019); a European palm-oil trade association’s health page (updated May 2021); a Vermont chocolate maker’s page on why palm oil is bad (undated); a health publisher’s palm oil article (updated 21 December 2023); and a medical school’s consumer health letter, “Is palm oil good for you?” (23 July 2024). Kept with this page’s records.
[2] Sun Y, Neelakantan N, Wu Y, Lote-Oke R, Pan A, van Dam RM. Palm oil consumption increases LDL cholesterol compared with vegetable oils low in saturated fat in a meta-analysis of clinical trials. Journal of Nutrition 2015;145(7):1549–1558. 32 studies in 30 articles, searched to May 2014; 27 against oils low in saturated fat, with 807 people at the start. Read in full in the Internet Archive’s copy of the journal’s PDF (captured November 2017); its supplement was not read. Supported by Singapore’s National Medical Research Council; all six authors declare no conflicts of interest. Of its 27 main trials, 15 were funded partly or wholly by industry. doi:10.3945/jn.115.210575
[3] Schwingshackl L, Bogensberger B, Benčič A, Knüppel S, Boeing H, Hoffmann G. Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis. Journal of Lipid Research 2018;59(9):1771–1782. 54 trials, 2,065 people, 13 oils and fats. Read in full on PubMed Central. Funded through a nutrition research cluster of Germany’s Federal Ministry of Education and Research, which had no role; no competing interests. doi:10.1194/jlr.P085522
[4] Zhang J, Ping W, Chunrong W, Shou CX, Keyou G. Nonhypercholesterolemic effects of a palm oil diet in Chinese adults. Journal of Nutrition 1997;127(3 Suppl):509S–513S. 120 men aged 18 to 25 with normal cholesterol, randomly assigned to palm oil, soybean oil, peanut oil or lard for six weeks, and a separate crossover of palm and peanut oil in 51 people with raised cholesterol; that crossover is in the 2015 pooling and the lard arm is not. Read in full in the Internet Archive’s copy of the journal’s page (captured October 2017); its tables, linked from that page, were not read, and the figures used here are in its text. Supported by a research grant from a Malaysian palm oil research institute; it was presented at a 1995 symposium whose proceedings were supported in part by a grant from a Malaysian palm oil promotion council. doi:10.1093/jn/127.3.509S
[5] The desk’s searches, 20 October 2026, for the two absence sentences on this page. Heart attacks, strokes and deaths: PubMed by title and abstract in two wordings (83 and 22 records), every title read; the wider class, tropical and coconut oil trials with heart outcomes (13 records); ClinicalTrials.gov, palm oil and palm olein with heart conditions (23 and 25 records), every title and main outcome read; the newest systematic review of palm oil and heart outcomes ([14]), which found no trial to June 2017; and an ordinary web search, its first page of results read. Cancer: PubMed in two wordings (5 and 53 records), every title read; ClinicalTrials.gov, palm oil and cancer (4 records); a 2013 review of palm oil and palmitic acid, which calls such studies “scanty”, and a 2024 scoping review of tropical oils; and an ordinary web search, its first page read. Run again by a corrector on 20 October 2026: PubMed for randomised trials of palm oil with heart events (18 records), for studies of palm oil and heart disease in people in two wordings (4 and 14 records, which found one study published after 2017, in Ethiopia) and for palm oil and cancer in people (24 records), every title read; ClinicalTrials.gov for both (18 and 3 records); and an ordinary web search for each. Every query and count is kept with this page’s records.
[6] Hisham MDB, Aziz Z, Huin WK, Teoh CH, Jamil AHA. The effects of palm oil on serum lipid profiles: a systematic review and meta-analysis. Asia Pacific Journal of Clinical Nutrition 2020;29(3):523–536. 23 studies from 21 trials, 706 people, searched to December 2019. Read in full in the journal’s own PDF. Supported by a University of Malaya grant; the authors declare no conflicts of interest. It reports that about half its trials were funded by a palm-oil organisation or by a company that supplied the comparison oil. doi:10.6133/apjcn.202009_29(3).0011
[7] Unhapipatpong C, Shantavasinkul PC, Kasemsup V, et al. Tropical oil consumption and cardiovascular disease: an umbrella review of systematic reviews and meta analyses. Nutrients 2021;13(5):1549. Nine meta-analyses, searched to December 2018. Read in full on PubMed Central. Funded by the Thai Health Promotion Foundation; no conflicts of interest declared. doi:10.3390/nu13051549
[8] Fattore E, Bosetti C, Brighenti F, Agostoni C, Fattore G. Palm oil and blood lipid-related markers of cardiovascular disease: a systematic review and meta-analysis of dietary intervention trials. American Journal of Clinical Nutrition 2014;99(6):1331–1350. 51 studies. Read in full in the Internet Archive’s November 2017 copy of the journal’s full-text page; an earlier archived copy is a paywall. Supported by a Milan university and an Italian chocolate and confectionery company that, the paper says, has “a financial interest in products containing” palm oil. That company funded one author for this work and two others in the previous three years, outside it, and a fourth author had been funded in the previous three years by an Italian confectionery and pasta industry association that “might have an interest in the outcome of the study”. The paper says the funders had no role in its design, analysis or interpretation. Of its 51 studies, 19 had the support of Malaysia’s palm oil board, 12 of private companies and 19 of public research bodies. doi:10.3945/ajcn.113.081190
[9] Voon PT, Lee ST, Ng TKW, Ng YT, Yong XS, Lee VKM, Ong ASH. Intake of palm olein and lipid status in healthy adults: a meta-analysis. Advances in Nutrition 2019;10(4):647–659. Nine randomised trials. Read in full on PubMed Central. Supported by Malaysia’s palm oil board, which it describes as a government research and development institution; two of its seven authors are research officers in the board’s nutrition unit, a third lists that unit as an affiliation beside a university where, the paper says, the author is a postgraduate student, and a fourth chairs a Malaysian association of oil scientists and technologists. The paper says the board played no role in its design, analysis or interpretation, and the authors declare no commercial interests. Its subgroup results against coconut oil and lard, monounsaturated oils and soybean oil were read from its LDL forest plot. doi:10.1093/advances/nmy122
[10] Wang F, Zhao D, Yang Y, Zhang L. Effect of palm oil consumption on plasma lipid concentrations related to cardiovascular disease: a systematic review and meta-analysis. Asia Pacific Journal of Clinical Nutrition 2019;28(3):495–506. 11 trials. Read in full in the journal’s own PDF. The authors declare no conflicts of interest and the paper names no funder for the review; its own table lists Malaysia’s palm oil board as the funder of 10 of its 11 trials. Its LDL chart, read from the images in its PDF, gives 42.6% of the weight to one study that its table calls a before-after study, although its rule was to include randomised trials only. doi:10.6133/apjcn.201909_28(3).0009
[11] World Health Organization. A rapid overview of systematic reviews on the effects of palm oil intake compared with intake of other vegetable oils on mortality and cardiovascular health in children and adults. Geneva: World Health Organization; 27 February 2024. ISBN 978-92-4-008834-4. Prepared for WHO’s Department of Nutrition and Food Safety by an evidence centre at Stellenbosch University, South Africa, with searches in March 2021 and January 2022; three of its preparers are partly supported by a project funded by the UK government. Read in full in WHO’s PDF. Its publication page, read 20 October 2026, says WHO is developing guidelines on tropical oils and that the overview is evidence for interim policy talks while countries wait for them. A report, not a study; it has no DOI.
[12] Voon PT, Ng CM, Ng YT, Wong YJ, Yap SY, Leong SL, Yong XS, Lee SWH. Health effects of various edible vegetable oil: an umbrella review. Advances in Nutrition 2024;15(9):100276. 48 reviews holding 206 meta-analyses, searched to 31 July 2023, graded with GRADE. Read in full on PubMed Central. Three of its eight authors give the nutrition unit of Malaysia’s palm oil board as their affiliation; the paper reports no funding, and its authors report no conflicts of interest. Its palm olein finding rests on one review, the board-funded 2019 palm-olein pooling. doi:10.1016/j.advnut.2024.100276
[13] Hyde PN, Sapper TN, LaFountain RA, Kackley ML, Buga A, Fell B, Crabtree CD, Phinney SD, Miller VJ, King SM, Krauss RM, Kraemer WJ, Volek JS. Effects of palm stearin versus butter in the context of low-carbohydrate/high-fat and high-carbohydrate/low-fat diets on circulating lipids in a controlled feeding study in healthy humans. Nutrients 2021;13(6):1944. Randomised controlled-feeding crossover, 24 adults with normal cholesterol in two diet tracks of 12, three weeks on each fat. Read in full on PubMed Central. Funded by Malaysia’s palm oil board; two authors report royalties from low-carbohydrate diet books and founding roles at a low-carbohydrate health company. doi:10.3390/nu13061944
[14] Ismail SR, Maarof SK, Siedar Ali S, Ali A. Systematic review of palm oil consumption and the risk of cardiovascular disease. PLoS One 2018;13(2):e0193533. Searched to June 2017. Read in full on PubMed Central. Written at Malaysia’s Institute for Medical Research; no specific funding; no competing interests. doi:10.1371/journal.pone.0193533
[15] Kabagambe EK, Baylin A, Ascherio A, Campos H. The type of oil used for cooking is associated with the risk of nonfatal acute myocardial infarction in Costa Rica. Journal of Nutrition 2005;135(11):2674–2679. 2,111 survivors of a first heart attack and 2,111 matched population controls. Read in full in the Internet Archive’s copy of the journal’s page (captured November 2016); its tables, linked from that page, were not read, and every figure used here is in its text. Supported by two US National Institutes of Health grants; the paper prints no conflict-of-interest statement. doi:10.1093/jn/135.11.2674
[16] Gebremedhin MH, Gebrekirstos LG. Dietary and behavioral risk factors of ischemic heart disease among patients of medical outpatient departments in southern Ethiopia: unmatched case-control study. Integrated Blood Pressure Control 2021;14:123–132. 140 patients with ischaemic heart disease and 417 hospital controls at three hospitals, November 2019 to March 2020, recruited by convenience sampling. Read in full on PubMed Central. The university paid the data collectors’ and supervisors’ daily allowances; the authors report no conflicts of interest. doi:10.2147/IBPC.S322663
[17] Chen BK, Seligman B, Farquhar JW, Goldhaber-Fiebert JD. Multi-country analysis of palm oil consumption and cardiovascular disease mortality for countries at different stages of economic development: 1980–1997. Globalization and Health 2011;7:45. 23 countries, adults aged 50 and over. Read in full on PubMed Central. A Stanford University fellowship and a US National Institutes of Health career award; the authors declare no competing interests. doi:10.1186/1744-8603-7-45
[18] EFSA Panel on Contaminants in the Food Chain (CONTAM). Risks for human health related to the presence of 3- and 2-monochloropropanediol (MCPD), and their fatty acid esters, and glycidyl fatty acid esters in food. EFSA Journal 2016;14(5):4426, with later editorial amendments and an erratum to its tables, none of which change the figures used here. The European Food Safety Authority’s opinion, requested by the European Commission. Read in the Internet Archive’s copy of the authority’s PDF (captured June 2025): its abstract, summary, occurrence tables and conclusions. doi:10.2903/j.efsa.2016.4426
[19] EFSA Panel on Contaminants in the Food Chain (CONTAM). Update of the risk assessment on 3-monochloropropane diol and its fatty acid esters. EFSA Journal 2018;16(1):5083. Read in full on PubMed Central. It does not re-assess glycidol. doi:10.2903/j.efsa.2018.5083
[20] Commission Regulation (EU) 2023/915 of 25 April 2023 on maximum levels for certain contaminants in food, Annex I, points 5.3 and 5.4. Read in the Internet Archive’s copy of the EUR-Lex text (captured February 2024), after EUR-Lex answered our request with an empty page. A regulation, not a study; it has no DOI.
[21] Beekman JK, Grassi K, MacMahon S. Updated occurrence of 3-monochloropropane-1,2-diol esters (3-MCPD) and glycidyl esters in infant formulas purchased in the United States between 2017 and 2019. Food Additives & Contaminants: Part A 2020;37(3):374–390. 222 formulas. Written by scientists at the US Food and Drug Administration. Read as its published abstract; its funding statement was not read. doi:10.1080/19440049.2019.1706002
[22] Pascual G, Domínguez D, Elosúa-Bayes M, et al. Dietary palmitic acid promotes a prometastatic memory via Schwann cells. Nature 2021;599(7885):485–490. A study in mice and cells. Read in full in the authors’ accepted manuscript, from the Internet Archive’s copy of a university repository’s file. Funded by European, Spanish and Catalan public research funds, cancer charities and foundations, and the US National Institutes of Health; the senior author is a co-founder and scientific adviser of a therapeutics company, and the other authors declare no competing interests. doi:10.1038/s41586-021-04075-0
[23] Genualdi S, MacMahon S, Robbins K, Farris S, Shyong N, DeJager L. Method development and survey of Sudan I–IV in palm oil and chilli spices in the Washington, DC, area. Food Additives & Contaminants: Part A 2016;33(4):583–591. Scientists at the US Food and Drug Administration. Read in full on PubMed Central. Funded within the agency; no conflicts of interest reported. Published online on 29 February 2016; it gives no dates for when the oils were bought. It notes that the WHO’s cancer agency, IARC, lists the Sudan dyes in group 3, which IARC’s own list (read 20 October 2026) defines as “not classifiable as to its carcinogenicity to humans”. doi:10.1080/19440049.2016.1147986
[24] Dong S, Xia H, Wang F, Sun G. The effect of red palm oil on vitamin A deficiency: a meta-analysis of randomized controlled trials. Nutrients 2017;9(12):1281. Nine randomised trials, in India, Africa, Honduras and China. Read in full on PubMed Central. Funded by a Chinese national science ministry programme, a Chinese university research fund and Malaysia’s palm oil board, which the paper says had no role; no competing financial interests. doi:10.3390/nu9121281
[25] US Department of Agriculture, FoodData Central, SR Legacy entries 171422 “Vegetable oil, palm kernel” (saturated fat 81.5 g per 100 g, of which lauric acid 47.0 g and palmitic acid 8.1 g), 171412 “Oil, coconut” (82.5 g), 173410 “Butter, salted” (51.4 g of saturated fat in 81.1 g of fat) and 171401 “Lard” (39.2 g). Read through the department’s public data service on 20 October 2026. A government database, not a study; it has no DOI.
[26] Mattson FH, Grundy SM. Comparison of effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. Journal of Lipid Research 1985;26(2):194–202. 20 patients. Read as its published abstract: no free full text was listed for it, and the Internet Archive’s copy of the journal’s page is an empty stub. PubMed lists two US National Heart, Lung, and Blood Institute grants; its funding statement was not read. doi:10.1016/S0022-2275(20)34389-3
[27] World Health Organization and Food and Agriculture Organization of the United Nations. Diet, nutrition and the prevention of chronic diseases: report of a joint WHO/FAO expert consultation. WHO Technical Report Series 916. Geneva: World Health Organization; 2003. Read in full in the Internet Archive’s copy of WHO’s PDF (captured May 2023). An expert report, not a study; it has no DOI.
[28] Kadandale S, Marten R, Smith R. The palm oil industry and noncommunicable diseases. Bulletin of the World Health Organization 2019;97(2):118–128. Read in full on PubMed Central. Written by authors at a UN children’s agency and two UK universities; no competing interests declared. doi:10.2471/BLT.18.220434
[29] World Health Organization. Guideline Development Group on consumption of tropical oils. Web page, read 20 October 2026: it says WHO “is planning to develop a guideline on consumption of tropical oils such as palm oil and coconut oil”, lists the group’s first meeting on 22–23 May 2024, and lists no tropical-oils guideline among its publications. A web page, not a study; it has no DOI.
[30] Odia OJ, Ofori S, Maduka O. Palm oil and the heart: a review. World Journal of Cardiology 2015;7(3):144–149. A narrative review, not a pooling of trials. Read in full on PubMed Central. The authors declare no conflict of interest; the article prints no funding statement. doi:10.4330/wjc.v7.i3.144